Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474197 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
A Phase 2 study of Alpha1-Antitrypsin Deficiency, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 20
- Study locations
NCT04474197 is a Phase 2 study of Alpha1-Antitrypsin Deficiency that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 44 participants, below the 152-participant average among 5 other Alpha1-Antitrypsin Deficiency trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04474197, a Phase 2 study of Alpha1-Antitrypsin Deficiency, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-864
Study Locations (20)
Florida
- University of Florida - Gainesville
- University of Miami Miller School of Medicine - Miami
- Central Florida Pulmonary - Orlando
California
- David Geffen School of Medicine at UCLA - Los Angeles
- University of California Davis Medical Center - Sacramento
Missouri
- Blessing Corporate Services, Inc., dba Blessing Health System - Hannibal
- Cardinal Glennon Children's Hospital - St. Louis University - St Louis
North Carolina
- University of North Carolina Medical Center - Chapel Hill
- Wake Forest University Baptist Medical Center - Winston-Salem
Texas
- Renovatio Clinical - Houston
- The University of Texas Health Science Center at Tyler - Tyler
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- National Jewish Health - Denver
Iowa
- The University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-07-24 |
| Est. Completion | 2021-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04474197
The ClinicalTrials.gov registry entry for NCT04474197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 5 other Alpha1-Antitrypsin Deficiency trials with a reported enrollment target (71% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha1-Antitrypsin Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04474197 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04474197 about?
NCT04474197 is a clinical study titled "Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype". This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
What is the current status of trial NCT04474197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2020-07-24. Estimated completion is 2021-05-04.
What conditions does trial NCT04474197 study?
This clinical trial studies the following conditions: Alpha1-Antitrypsin Deficiency.
What interventions are being tested in trial NCT04474197?
The interventions under investigation include: Placebo (DRUG), VX-864 (DRUG).
Who is sponsoring clinical trial NCT04474197?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474197 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha1-Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
RECRUITING
-
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
RECRUITING · Phase 3
-
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
RECRUITING · Phase 3
-
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.